The New Frontier of Pharmaceutical Growth

The pharmaceutical industry is facing a paradox: markets can grow in value while treating fewer patients. Mexico illustrates this shift clearly. Its pharmaceutical market reached US$22.6 billion in MAT March 2026, growing 6.7% in value while declining 2.2% in units. In other words, growth is being driven by price and product mix rather than by an increase in the number of patients treated. 

This raises a critical question for the industry: Where will sustainable volume growth come from? The answer may lie beyond the prescription itself in what happens after the patient leaves the doctor's office. 

One in four patients leaves a medical appointment without clarity about the next step in their treatment. Seventy percent say a proactive AI check-in could reduce that confusion, while 89% of Mexican patients say automatic reminders would improve their adherence, the highest figure in the global study. Among patients with chronic conditions, 65% believe a 24/7 digital companion could significantly facilitate disease management. 

The opportunity extends beyond reminders. Seventy-seven percent of patients complete more medical referrals when they receive digital notifications, 83% want proactive recommendations for self-enrollment, and 73% would trust AI to identify drug interactions. These figures suggest that the patient journey is becoming an increasingly important driver of healthcare value. 

At the same time, Mexico is demonstrating how rapidly patient behavior is changing. Sixty-six percent of Mexican patients used generative AI for health-related topics in the previous 30 days. More importantly, 80.8% use AI in ways that strengthen the physician-patient relationship, either by using it as initial guidance or to better prepare for a medical consultation. Only a minority uses AI to make decisions without consulting a physician. 

This challenges one of the industry's central assumptions: that AI will replace the physician. The evidence points in another direction. Patients are increasingly using AI to arrive at consultations better informed, while physicians are incorporating it into their own workflows. In Mexico, only 6.3% of physicians report using AI outputs without validating them against guidelines, scientific literature or colleagues. 

Adoption, however, comes with a condition: trust. In Mexico, 66% of patients prefer an AI agent integrated into their physician's environment, compared with only 21% who prefer an open public chatbot. Globally, patients are three times more likely to trust an agent integrated into their provider's secure environment than a public chatbot. 

Patients are also demanding clear safeguards. Between 88% and 90% want human oversight depending on the task, while 89–90% expect a clear path to escalation to a person. Between 85% and 88% want to know where information comes from, and 81–88% want traceability of the reasoning behind AI outputs. 

The shift is also reshaping pharmaceutical engagement. Medical-representative interactions declined 10.2%, while face-to-face interactions fell from 90% to 68%. At the same time, non-traditional channels, including e-pharmacies, direct-to-consumer models, subscriptions and digital health, are emerging as growth engines. 

This transformation makes continuous patient engagement increasingly relevant. The opportunity is particularly significant for generic medicines: preference for generics has increased 31% over five years, from 46% to 59% of purchases, with 85% citing savings and 65% availability at the point of sale as key drivers. Brand medicines retain a premium of only around 18%. 

As affordability and availability continue to support generic adoption, the next competitive advantage may come from everything surrounding the medicine: access, reminders, refills, navigation, education and personalized follow-up. 

The pharmaceutical industry's traditional growth model has largely focused on generating demand and increasing market share. But when a market grows 6.7% in value while declining 2.2% in units, gaining share from competitors is no longer enough. The industry needs to expand the number of patients who successfully remain on treatment. 

That is why adherence is becoming more than a patient-support initiative. It is emerging as a strategic growth lever. The greatest opportunity may be hidden in the moments that follow the consultation: the patient who does not understand the next step, the prescription that is not refilled on time, the treatment that is interrupted, or the person who needs a simple reminder to stay on track. 

Mexico is already showing the scale of this opportunity. Eighty-nine percent of Mexican patients say automatic reminders would improve their adherence, while 70% say proactive AI follow-up could reduce uncertainty after a consultation. 

The industry's next frontier, therefore, is not simply prescribing more. It is building a continuous, personalized and trusted connection between the patient, the treatment and the healthcare professional. In a market where volume is declining, companies that successfully transform the period after the prescription into an experience of support, clarity and continuity may create something more valuable than market share: more treated patients who remain on therapy.